Dapoxetine is a selective serotonin reuptake inhibitor used in the treatment of premature ejaculation. In a phase II proof-of-concept study conducted by PPD, dapoxetine demonstrated a statistically significant increase in ejaculatory latency when compared to placebo.
- Mechanism
- Curator reviewed
The drug's mechanism of action is thought to be related to inhibition of neuronal reuptake of serotonin and subsequent potentiation of serotonin activity. The central ejaculatory neural circuit comprises spinal and cerebral areas that form a highly interconnected network. The sympathetic, parasympathetic, and somatic spinal centers, under the influence of sensory genital and cerebral stimuli integrated and processed at the spinal cord level, act in synergy to command physiologic events occurring during ejaculation. Experimental evidence indicates that serotonin (5-HT), throughout brain descending pathways, exerts an inhibitory role on ejaculation. To date, three 5-HT receptor subtypes (5-HT(1A), 5-HT(1B), and 5-HT(2C)) have been postulated to mediate 5-HT's modulating activity on ejaculation.
- Primary indication
- For the treatment of premature ejaculation.Curator reviewed · 3 structured indications
- Formula / weight
- C21H23NO · 305.4134 g/mol (avg)
- Code names
- LY-210448
Resolves to
USRHYDPUVLEVMC-FQEVSTJZSA-NSMILESCN(C)[C@@H](CCOC1=CC=CC2=CC=CC=C12)C1=CC=CC=C1What you can answer from here — as of September 23, 2026
Which drugs share a target with Dapoxetine, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account